Answers are grounded in this paper and cite their sources.
A number of hematopoietic growth factors and other cytokines are capable of altering platelet production and function. Enhancement of these processes may be exploited to ameliorate bleeding propensity in thrombocytopenic patients. Under certain circumstances, cytokines may have adverse effects on the hemostatic system, potentially involved in thrombogenesis and atherogenesis. Inhibition of those cytokines may prove to be a useful experimental approach to investigate their potential pathophysiologic role.
No takes yet. Share an insight, caveat, or question.
Samuel A. Burstein (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: